# reload+after+2024-01-20 06:43:31.097578
address1§2380 Conejo Spectrum Street
address2§Suite 200
city§Thousand Oaks
state§CA
zip§91320
country§United States
phone§805 623 4211
website§https://www.atarabio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
fullTimeEmployees§334
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Pascal  Touchon D.V.M.', 'age': 60, 'title': 'President, CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 1077856, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. K. Amar Murugan', 'age': 47, 'title': 'Executive VP & Chief Legal Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 618524, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric  Hyllengren', 'age': 48, 'title': 'Senior VP & CFO', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Anhco  Nguyen Ph.D.', 'age': 50, 'title': 'Executive VP and Chief Scientific & Technical Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Alex  Chapman', 'title': 'Vice President of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Manher  Joshi M.D.', 'title': 'Executive VP & Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jill  Henrich', 'age': 60, 'title': 'Executive VP and Global Head of Regulatory Affairs & Quality', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dan  Maziasz', 'title': 'Executive VP & Chief Business Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§5
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
priceToSalesTrailing12Months§9.940873
currency§USD
dateShortInterest§1702598400
forwardEps§-1.42
exchange§NMS
quoteType§EQUITY
shortName§Atara Biotherapeutics, Inc.
longName§Atara Biotherapeutics, Inc.
firstTradeDateEpochUtc§1413466200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2e7d1e9f-6492-3d1e-8dac-1008d2ea8165
gmtOffSetMilliseconds§-18000000
targetHighPrice§13.0
targetLowPrice§0.5
targetMeanPrice§4.83
targetMedianPrice§2.9
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§4
quickRatio§1.297
grossMargins§-0.26068002
ebitdaMargins§0.0
trailingPegRatio§None
